BOSTON, May 15, 2019 /PRNewswire/ -- Proteostasis
Therapeutics, Inc. (NASDAQ: PTI), a clinical stage
biopharmaceutical company dedicated to the discovery and
development of groundbreaking therapies to treat cystic fibrosis
(CF) and other diseases caused by dysfunctional protein processing,
today announced that Proteostasis management will present at the
2019 RBC Capital Markets Global Healthcare Conference on
Wednesday, May 22, 2019 at
9:00 a.m. ET at the InterContinental
New York Barclay.
A live audio webcast of the RBC Capital Markets Global
Healthcare Conference presentation will be available on the
Investor Events page in the Investors & Media section of the
Company's website, www.proteostasis.com. A replay of the webcast
will be available on the Company's website following the
presentation.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage
biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional
protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team
focuses on identifying therapies that restore protein function. For
more information, visit www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "aim," "may," "will," "expect,"
"anticipate," "estimate," "intend," and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Examples of forward-looking statements
made in this release include, without limitation, statements
regarding the expected presentation at an upcoming
conference. Forward-looking statements made in this release
involve substantial risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Such risks and uncertainties include,
without limitation, the uncertainties inherent in the execution and
completion of clinical trials, in the timing of availability of
trial data, in the results of the clinical trials, in the actions
of regulatory agencies, in the commercialization and acceptance of
new therapies, and those set forth in our Annual Report on Form
10-K for the year ended December 31,
2018, our Quarterly Report on form 10-Q for the quarter
ended March 31, 2019, and our other
SEC filings. We assume no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:
Investors:
David Pitts
/ Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-to-present-at-the-2019-rbc-capital-markets-global-healthcare-conference-300850346.html
SOURCE Proteostasis Therapeutics, Inc.